<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091854</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190530-01-KS-01</org_study_id>
    <nct_id>NCT04091854</nct_id>
  </id_info>
  <brief_title>The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Study to Observe the Progress of Diabetes Mellitus After 52 or 28 Weeks of HMS5552 Treatment for Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Majianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there are few studies on the clinical remission rate of diabetes after one year&#xD;
      discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of&#xD;
      GKA hypoglycemic drug. This study intends to observe the clinical remission rate of diabetes&#xD;
      mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes&#xD;
      mellitus who have been treated with HMS5552 for 52W or 28W and whose glucose control is up to&#xD;
      the standard.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes of HbA1c</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes of fasting glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes of postprandial glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C peptide</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>Changes of C peptide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes of TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes of IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-iso PGF2α</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes of 8-iso PGF2α</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HMS5552 treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus</description>
    <arm_group_label>HMS5552 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In this study, subjects with type 2 diabetes mellitus treated with HMS5552 were screened to&#xD;
        meet the target of glucose control when they completed 52 or 28 weeks of HMS5552 treatment&#xD;
        respectively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complete HMS5552 treatment and safety visit;&#xD;
&#xD;
          -  HbA1c &lt; 8.0% was detected in our laboratory;&#xD;
&#xD;
          -  Researchers judged the stability of glucose control based on the data of&#xD;
             subjects'visits during HMS5552 treatment and the indicators of our hospital;&#xD;
&#xD;
          -  Subjects are able and willing to monitor peripheral blood sugar and regularity of diet&#xD;
             and exercise;&#xD;
&#xD;
          -  Willing to sign written informed consent and abide by the research program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There was a state of illness in the subjects who could not complete the follow-up&#xD;
             during the observation period.&#xD;
&#xD;
          -  The researchers judged that subjects'compliance with HMS5552 was affected during&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing First hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Majianhua</investigator_full_name>
    <investigator_title>Director, Head of Endocrinology department, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Glucokinase Activator</keyword>
  <keyword>Glucose control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

